InspireMD (NSPR) Q4 2025 Earnings Transcript

InspireMD reported Q4 revenue of $3.1 million, up 62% year over year, driven by the U.S. launch of CGuard Prime, while gross margin expanded to 37.5% from 24.1%. The company guided 2026 revenue to $13 million-$15 million, implying 45%-65% growth, and said enrollment has concluded in its C-GUARDIANS II trial with FDA approval for the TCAR indication targeted for Q3. Management also highlighted more than 500 U.S. cases, an 80-center footprint, and a pipeline of 200+ centers, but losses widened to $11.8 million as commercial spending increased.

Analysis

NSPR is transitioning from a science story to a commercial-execution story, and that changes the stock’s driver set. The near-term winner is not just the company but also the channel infrastructure around carotid intervention: IDNs, VAC committees, and rep-supported procedure volumes become the bottleneck, which means adoption should be lumpy rather than linear. That favors a “few centers matter a lot” model early on, where incremental account wins can create visible step-ups in revenue, but also makes quarter-to-quarter comparisons noisy because case timing can swing gross margin and OPEX leverage.

The real second-order catalyst is the TCAR label expansion because it widens the procedure universe without requiring a new clinical franchise from scratch. If approval lands in Q3, the market will likely re-rate the name before revenue inflects, since the commercial team is already in place and the pipeline suggests the company is setting up for a faster conversion curve in 2H26. The implication for competitors is that legacy carotid players face a gradual but potentially meaningful share-grab in high-acuity centers; more importantly, once physicians standardize on one stent in both CAS and TCAR workflows, switching costs rise and can compress competitor pricing power.

The contrarian point is that the current setup may underappreciate how much of 2026 is still infrastructure investment, not harvested growth. The company can be “right” on product and still miss on timing if VAC approvals or center activations slip by a quarter or two, which matters because the business is still small enough that execution noise dominates fundamentals. The financing overhang is also asymmetric: the milestone tranches are effectively growth-contingent dilution, so a positive catalyst can come with a lower per-share benefit than bulls expect.

Watch for two reversal signals: slower-than-expected center conversion in the next 2 quarters, and any delay in the FDA path for TCAR or the delivery-system update. If either happens, the stock can de-rate quickly because the market is currently paying for an acceleration narrative rather than current earnings power.

Key Decisions for Investors

• Long NSPR into the late-April C-GUARDIANS II data readout, but size it as a catalyst trade, not a core hold; risk/reward improves if the stock has already pulled back on low liquidity and can be exited into the event.
• If the stock rallies into Q3 FDA timing, sell upside via call spreads or trim strength; the market may overcapitalize the TCAR approval before reimbursement, center conversion, and repeat-case economics are visible.
• Consider a paired relative-value trade: long NSPR / short a mature carotid-device incumbent proxy, expressing share-gain optionality while reducing broader medtech market beta; monitor whether NSPR’s center adds outpace competitive response over 2-3 quarters.
• Avoid buying size ahead of the milestone tranche trigger windows unless you explicitly want the dilution-funded growth trade; the cash raise is likely to cap upside per share if commercial traction accelerates.
• For higher-risk accounts, use a small starter position and add only after evidence that >200-center pipeline is converting into repeat accounts; the key variable is not first-case volume but repeat utilization per center over the next 2-4 quarters.